The Multicenter Prospective Randomized Controlled Trial Evaluating Efficacy of Pharmacological Approaches to Improve Long-Term Outcome of Catheter Ablation for Atrial Fibrillation: Kansai Plus Atrial Fibrillation (KPAF) trial

The Multicenter Prospective Randomized Controlled Trial Evaluating Efficacy of Pharmacological Approaches to Improve Long-Term Outcome of Catheter Ablation for Atrial Fibrillation: Kansai Plus Atrial Fibrillation (KPAF) trial - KPAF trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006127

Enrollment

2000

Registered

2011-08-08

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial Patients are randomized in a 1:1 ratio to control or ATP groups. Following successful pulmonary vein (PV) isol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing first catheter ablation for paroxysmal or persistent atrial fibrillation, who are 21-79 years old, able to be followed for one year in an out-patient clinic and willing to sign the consent form for participation, are eligible for the study.

Exclusion criteria

Exclusion criteria: 1) Patients who are intolerant for ATP or antiarrhythmic drugs (Vaughan Williams class I or III), including those in acute phase of intracranial bleeding and those with severe bronchial asthma, severe vasospastic angina, substantial bradycardia, a history of allergy for ATP or antiarrhythmic drugs or a history of severe adverse effect of ATP or antiarrhythmic drugs. 2) Patients equal or younger than 20 years and those equal or older than 80years 3) Patients who are unable to be followed in an out-patient clinic for one year 4) Patients with renal insufficiency (serum creatinine >=2.0mg/dl or hemodialysis) 5) Patients with NYHA class IV heart failure 6) Left ventricular ejection fraction < 40% 7) Left atrial diameter > 55mm 8) Very long-lasting (>=5years) persistent atrial fibrillation 9) Patients ineligible for optimal anticoagulant therapy 10) Patients with a history of myocardial infarction within the past 6 months 11) Patients with a history of open heart surgery 12) Patients with a planned open heart surgery 13) Patients with severe valve heart disease 14) Patients unwilling to sign the consent form for participation 15) When the attending physician are unwilling to enroll the patient in the study 16) When the attending physician consider inappropriate to enroll the patient in the study

Design outcomes

Primary

Measure	Time frame
Event-free rate from atrial tachyarrhythmia after catheter ablation for atrial fibrillation.	—

Countries

Japan

Contacts

Public ContactSatoshi Shizuta

Kyoto University Graduate School of Medicine Department of Cardiovascular Medicine

shizuta@kuhp.kyoto-u.ac.jp075-751-4255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026